This is an accordion element with a series of buttons that open and close related content panels.
NIDDK FUNDING ANNOUNCEMENTS
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (observational studies) – This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. A letter of intent is required 30 days prior to submission. Next standard due date: June 5, 2021 (standard dates apply). Expires 1/08/2024.
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (clinical trials) – This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. A letter of intent is required 30 days prior to submission. Next standard due date: June 5, 2021 (standard dates apply). Expires 1/08/2024.
Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional) The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational and clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. Overall objectives of the SUITOR program are to broaden the conceptual framework of urologic research, to promote productive interdisciplinary research collaborations, and ultimately to catalyze discoveries in basic, translational, clinical and/or epidemiological research that will provide new insights into the pathogenesis, prevention, detection, and potential treatment of disease. Next standard due date: June 5, 2021 (standard dates apply). Expires 5/8/2022
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK.
- Scope. The activities required in the U34 will depend on the type of study (e.g., epidemiologic study, drug/device/biologics trial, behavior intervention). Because the purpose of the U34 is primarily for the conduct of administrative tasks needed to prepare for participant recruitment, activities involving human subjects will generally not be conducted during the U34 phase; however, brief activities involving interactions with individuals similar to those expected to participate in the full study during the U01 award may be allowed in order to aid in development of study procedures or operations (e.g., assessing usability of a form, device calibration, workflow optimization). As noted above, the U34 period may also include stakeholder engagement activities. First standard due date: June 9, 2021 (letter of intent due May 9, 2021)
High impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of NIDDK.
NIDDK envisions that RC2 projects will:
- take novel approaches to address specific knowledge gaps in the field of interest to NIDDK
- take advantage of scientific opportunities
- develop new technologies; and/or
- generate data or research methods that are useful for the scientific community
FOA posted 2/27/2019. Upcoming application due dates: June 1, 2021; November 2, 2021 , by 5:00 PM local time of applicant organization. LOI due six weeks prior to application due date.
OTHER NIH FUNDING ANNOUNCEMENTS
From the National Institute on Aging:
Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: (1) curriculum or methods development; (2) courses for skills development; and/or (3) research experiences. Next standard due date: May 25, 2021 (standard dates apply). Expires 1/26/2023.
Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) Aging research frequently entails a multidisciplinary effort, drawing on the expertise and resources of multiple individuals, institutions, and communities. Some studies require large-scale approaches requiring coordination of multiple components or across multiple sites in order to leverage a wide range of necessary resources and expertise. However, the scale and complexity of such projects are often unsuitable for traditional NIH mechanisms (e.g., R01) and instead require more specialized mechanisms to successfully coordinate their multiple interacting components and allow for adequate presentation of the breadth and complexity of the proposed project to peer reviewers.
- Scope. This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions.
- Next standard due date: May 25, 2021 (standard dates apply). LOI due 30 days prior to application due date. Expires 9/26/2022.
Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 – Clinical Trial Optional) This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions. Next standard due date: June 16, 2021 (standard dates apply). Expires 11/17/2022.
From other NIH institutes:
- Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed) Office of Strategic Coordination (Common Fund). The Transformative Research to Address Health Disparities and Advance Health Equity initiative is soliciting applications to support collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate health disparities and advance health equity. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in addressing health disparities and inequities. LOI due 4/28/2021; application due 5/28/2021.
- Surgical Disparities Research (R01 – Clinical Trial Optional) National Institute on Minority Health and Health Disparities. The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional and systems level. LOI due 30 days prior to application due date; application due dates: June 5, 2021, June 5, 2022.
- Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 – Clinical Trial Optional) Agency for HealthCare Research and Quality. The Agency for Healthcare Research and Quality’s (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Next standard due date: June 16, 2021 (standard dates apply); no LOI required; expires: July 18, 2024.
- Research Supplements to Promote Diversity in Health-Related Research NIH-wide announcement. Funds are available to program directors and principal investigators holding specific types of NIH research grants for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. Administrative supplements must support work within the scope of the original project. The application deadline varies by Institute or Center. This is an administrative supplement; clinical trial not allowed. Posted 11/16/2020; expires: May 8, 2023.
OTHER FUNDING OPPORTUNITIES
Department of Defense (DoD) Spinal Cord Injury Research Program The Spinal Cord Injury Research Program (SCIRP) was established by Congress in fiscal year 2009 (FY09), in part as a response to the high rates of SCI observed in Warfighters returning home from duty. SCIRP’s mission is to fund research and encourage multidisciplinary collaborations for the development and translation of more effective strategies to improve the health and well-being of Service members, Veterans, and other individuals with spinal cord injury. Applications submitted to the FY21 SCIRP must address one or more of the identified focus areas, which includes genitourinary issues:
Rising Stars in Urology Research Awards The Rising Stars in Urology Research Award program presented by the American Urological Association provides up to five years of supplemental salary support to urologists who have successfully competed for career development awards from the National Institutes of Health (NIH) or other major funding organizations. These awards ensure that the salary compensation for those committed to careers in urologic research remain competitive with that of their clinical urology peers. The program encourages recipients to contribute to urology as both surgical specialists and scientists investigating causes, prevention, treatment and cures that will improve patients’ lives. Letter of intent due May 20, 2021; application deadline June 3, 2021. More information can be found HERE.
Physician Scientist Residency Training Award Medical students in their senior year and recent medical school graduates who have a passion for urology and research will be invited to apply for the American Urological Association’s 2022 Physician Scientist Residency Training Award (PSRTA). The PSRTA Trainee will complete a three-year, research-intensive training program embedded within urology residency at an approved PSRTA Program Site and will receive $75,000 per year during the three-year research period. A letter of intent is required and is due by 5:00 p.m. Eastern on July 29, 2021. The application deadline is September 9, 2021.
The Oxalosis & Hyperoxaluria Foundation Global Registry Initiative The OHF is seeking proposals to develop international collaborative patient registries and databases to identify the determinants of the clinical manifestations and prognosis of patients with primary hyperoxaluria. As part of its wider mission to improve the understanding and treatment of primary hyperoxaluria and related calcium oxalate kidney stone diseases, the Oxalosis & Hyperoxaluria Foundation is interested in receiving proposals from scientists and clinicians that address the issue of the influence of genetic, cultural, and environmental background on the clinical manifestations and prognosis of patients with primary hyperoxaluria. To this end, financial support will be given to international collaborative projects that develop and make use of well-defined patient cohorts covering a wide range of genetic and cultural backgrounds. More information can be found HERE.
American Association of University Women AAUW American Fellowships support women scholars who are pursuing full-time study to complete dissertations, conducting postdoctoral research full time, or preparing research for publication for eight consecutive weeks. Applicants must be U.S. citizens or permanent residents. Candidates are evaluated on the basis of scholarly excellence; quality and originality of project design; and active commitment to helping women and girls through service in their communities, professions, or fields of research. Membership NOT required for application. There are three types of American Fellowship opportunities (see below); More information can be found HERE. Deadline for all is November 1, 2021.
- DISSERTATION FELLOWSHIPS
- POSTDOCTORAL RESEARCH LEAVE FELLOWSHIPS
- SHORT-TERM RESEARCH PUBLICATION GRANTS